Cutaneous hemangiomas are benign tumors formed by an abnormal vascular growth or proliferation of blood vessels in the skin. At Protheragen, we understand the critical need for a robust and integrated platform to support the development of novel therapies for conditions like cutaneous hemangioma. Our services are designed to address every stage of the preclinical research and development pipeline, from initial target identification to in-depth safety and efficacy validation.
Overview of Cutaneous Hemangioma
Cutaneous hemangioma, especially infantile hemangioma (IH), is recognized as a benign vascular tumor exhibiting a unique biphasic development. It initiates with a proliferative phase featuring increased division of endothelial cells and tumor growth, which often occurs during the neonatal period or early infancy. This is followed by a phase of spontaneous involution, during which lesions resolve gradually, and most lesions complete involution by age nine. While many IHs are benign, some can lead to complications like ulceration, bleeding, or significant disfigurement, which require intervention.
Fig.1 Congenital cutaneous hemangioma in a lamb. (Nascimento K. A.,
et al., 2022)
Pathogenesis of Cutaneous Hemangioma
The etiology of cutaneous hemangioma remains complex and multifactorial. Dysregulated vasculogenesis and angiogenesis are central to its development. Hypoxia is a key trigger, leading to the overexpression of angiogenic factors such as vascular endothelial growth factor (VEGF) via the hypoxia-inducible factor-2 alpha (HIF-2 alpha) pathway. Additionally, basic fibroblast growth factor (bFGF) and matrix metalloproteinases (MMPs) are upregulated during the proliferative phase, promoting endothelial cell proliferation. Hemangioma stem cells (HemSCs) have been identified and are believed to differentiate into endothelial cells, adipocytes, and pericytes, contributing to IH formation. The renin–angiotensin–aldosterone (RAA) axis may also play a role, with its components being expressed in IH-derived cells and their levels elevated in patients with IH.
Diagnostics Development for Cutaneous Hemangioma
- Histopathological Analysis
Histopathological examination is a cornerstone of cutaneous hemangioma diagnostics. Tissue samples reveal proliferating endothelial cells forming vascular spaces and channels. The presence of mast cells and other immune cells during the involution phase is also noted. This detailed histological analysis helps in confirming the diagnosis and understanding the tumor's stage and behavior.
- Immunohistochemical Characterization
Immunohistochemistry is crucial for identifying specific markers and understanding the different phases of hemangioma development. For example, GLUT1 is a specific marker for infantile hemangiomas, aiding in distinguishing them from other vascular anomalies. This method enhances diagnostic accuracy and provides insights into the underlying biological processes.
- Imaging Techniques
Advanced imaging techniques such as Doppler ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans are increasingly used in the diagnostic development of cutaneous hemangioma. These modalities provide detailed information about the size, depth, and blood flow characteristics of the lesion, aiding in the assessment of potential complications and guiding therapeutic decisions.
Therapeutics Development for Cutaneous Hemangioma
- Beta-Blockers
Propranolol has revolutionized the therapeutic of infantile hemangioma. It acts through multiple mechanisms, including vasoconstriction, reducing the levels of growth factors like VEGF and MMPs, and promoting apoptosis. Its efficacy and safety profile have made it the drug of choice for treating proliferating IHs.
- Corticosteroids
Systemic corticosteroids were historically used to inhibit the growth of IHs and accelerate their regression. While effective, they are associated with significant side effects, limiting their use to severe cases where other therapeutics are not suitable.
Our Services
Protheragen is a trusted partner in the development of diagnostics and therapeutics for cutaneous hemangioma. We offer a comprehensive suite of services that can be expressed in various forms to support our clients' research endeavors. These include, but are not limited to, contract research services for preclinical studies, the development of novel drug delivery systems, and the provision of analytical and formulation development expertise.
Disease Models
- Hemangioma-Derived Endothelial Cell Lines
- Vascularized Skin Organoids
- Blood Vessel Organoids
- VEGFR2-Overexpressing Mice
- Nude Mouse Hemangioma Xenograft Models
Protheragen offers comprehensive preclinical research services for cutaneous hemangioma, aimed at advancing innovative diagnostic and therapeutic solutions. With our cutting-edge facilities and a highly skilled team, we conduct extensive preclinical studies to ensure that every therapeutic candidate is meticulously evaluated for efficacy and safety. If you are interested in our services, please feel free to contact us.
Reference
- Nascimento, Karla Alvarenga, et al. "Congenital cutaneous hemangioma in a newborn Lamb." Acta Scientiae Veterinariae 50 (2022).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
